Erasca (ERAS) Corporate presentation summary

Vision and leadership

• Aims to erase cancer in at least 100,000 patients annually as a leading global oncology company.

• Founded by experts in RAS biology, supported by a world-class scientific advisory board with deep RAS/MAPK expertise.

• Leadership team has a strong track record in global drug development and execution.

Pipeline and scientific differentiation

• Pipeline focuses on shutting down the RAS/MAPK pathway, targeting RAS-mutated (RASM) and KRAS-mutated (KRASM) solid tumors.

• ERAS-0015 is a pan-RAS molecular glue with best-in-class potential; ERAS-4001 is a pan-KRAS inhibitor with first-in-class potential.

• Both candidates show strong preclinical and early clinical activity, with ERAS-0015 demonstrating superior potency, tumor distribution, and safety compared to competitors.

Clinical data and efficacy

• ERAS-0015 achieved high objective response rates (uORR) in 2L+ KRAS G12X NSCLC (up to 75%) and PDAC (up to 57%) at recommended doses.

• Durable responses and favorable safety profile observed, with most responders remaining on treatment in both US and China trials.

• Early data suggest improved efficacy and tolerability over RMC-6236, with lower rates of high-grade adverse events and dose modifications.